

Claims: What is claimed is:

1. An improved method of hormonal treatment of breast cancer and said hormonal
treatment comprising of breast implants of anti-estrogens and steroid hormones, or its
5 synthetic derivatives in one or more slow release formulations and permitting said
drugs to be continuously released at near constant rate directly to the breast for longer
periods with minimal or no systemic toxicity.
2. A method according to claim 1 further comprising release of said anti-estrogen and
10 hormonal compositions to the breast for extended periods by diffusion and
biodegradation from said breast implants in sufficient amounts to saturate the binding
sites for said drug compositions in the breast and to exert their maximum tumor
control activity.
- 15 3. A method of claim 1 wherein said implants comprising of hormonally effective
compositions selected from the anti-estrogen groups consisting of tamoxifen,
raloxifene and toremifene, and from the hormonal groups consisting of progesterones
and corticosteroids.
- 20 4. A method according to claim 1 wherein said prostatic implants of said drug
compositions are made as separate or in combination thereof.

mediums like normal saline, a local anesthetic and ethanol in a sterile syringe for direct injection to the breast as chelating slow release formulations when it comes in contact with breast tissue.

- 5 10. The method of claim 1 wherein said breast implants are selected from readily available commercial pharmaceutical preparations of anti-estrogens steroid hormones or their derivatives and said implants containing a single or multiples of said drug formulations for their slow release direct to the breast.

- 10 11. An improved method of concomitant hormonal and radiation treatment of the breast cancer and said hormonal treatment comprising of breast implants of anti-estrogens and steroid hormones in one or more slow release formulations and permitting said drugs to be continuously released at near constant rate directly to the breast during the radiation therapy and afterwards for longer periods.

- 15 12. An improved method of concomitant hormonal and radiation treatment of the breast cancer according to claim 11, wherein said continued slow release of hormonal composition directly to the breast during the interstitial radioactive seeds implants and afterwards for longer periods.

- 20 13. An improved method of concomitant hormonal and radiation treatment of breast cancer according to claim 11, wherein said hormonal implants to the breast is

performed concomitantly with the radioactive implants to improve cure and convenience to patient than when they are implanted separately.

14. An improved method of treating hormone dependent and hormone refractory breast cancer and its accessible metastasis by implanting combinations of hormones and anti-estrogens to said tumor sites for improved tumor control with lesser toxicity than by administering said hormonal compositions at higher doses by mouth, subcutaneous, intramuscular or intravenous routes and said hormone compositions containing in one or more slow release implant formulations.
15. A method of claim 14, wherein said breast, subcutaneous or intramuscular hormonal implants methods comprising implanting single or synergetic combination of hormonally and cytotoxically effective compositions selected from the anti-estrogen groups consisting of tamoxifen, raloxifene and toremifene and from the hormonal groups consisting of iodo-estradiol, progesterones, corticosteroids and they are fused with a lipoid carrier or encapsulated in Silastic capsules or formulated as injectable microcapsules as suitable slow-release breast, subcutaneous or intramuscular implant.
16. A method of claim 14, wherein said slow-release breast implant of anti-estrogen and hormonal compositions for treating breast cancer and providing minimum or no toxicity as compared to when said drug compositions are administered by oral routes daily.

17. A method of claim 14, wherein high concentrations of said drug composition to the breast is achieved by implanting said formulations directly to the breast and to derive the added beneficial effect from these breast implants on breast cancer by inhibiting the hypothalamic-pituitary LHRH, FSH and LH secretion by these composition's systemic contents.

18. Slow-release anti-cancer breast implants products for treatment of breast cancer and comprising of anti-estrogens and steroid hormones as fused with a lipoid carrier or as encapsulated in Silastic capsules or as injectable microcapsules and are suitable for breast implantation such that said hormonally and cytotoxically effective compositions are continuously released at relatively high constant rates to the breast.

19. The said products of claim 18 being further characterized by providing effective tumor control and having minimum or no systemic toxicity associated with said composition's breast implants than if they were daily administered orally for several years at much higher doses to achieve the same results.

20. Slow-release anti-cancer prostate implant product of claim 18, wherein said single drug formulation is made from any one of the anti-estrogen drugs from a group consisting of tamoxifen, raloxifene or toremifene and hormonal compositions consisting of progesterone, androgens or prednisolone.

21. Slow-release anti-cancer breast implant product of claim 18, wherein said synergetic two drugs formulations comprises of an anti-estrogen from the groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected from the group consisting of megestrol acetate, medroxyprogesterone, norethindrone acetate or norgestrel or from the corticosteroids groups, the prednisolone.

22. Slow-release anti-cancer breast implant product of claim 18, wherein said synergetic three drugs formulations comprises of an anti-estrogen from the groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected from the group consisting of megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from the corticosteroids group prednisolone.

23. Anti-cancer products of claim 18, wherein said compositions comprising of single or synergetic combination of hormonally and cytotoxically effective amount of an anti-estrogen from the groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected from the group consisting of megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from the corticosteroids group prednisolone as fused with a lipoid carrier suitable for prostatic implantation.

24. Anticancer products according to claim 18, wherein said single or synergetic combination of hormonally and cytotoxically effective amounts of formulations as

fused with a lipoid carrier suitable for breast implantation such that said compositions are continuously released at relatively constant rates to the breast for longer periods and the contents of said compositions being kept in amounts effective to suppress tumor growth with minimum or no systemic toxicity than if said drug compositions were administered daily by oral routes at much higher doses to achieve the same results as by said low dose breast implants.

25. Anticancer products of claim 18, wherein said single or synergetic combinations of hormonally and cytotoxically effective amounts of an anti-estrogen from the groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected from the group consisting of megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from the corticosteroids group prednisolone in same or separate slow release Silastic capsules suitable for prostatic implantation.

26. Anticancer products according to claim 18, wherein said single or synergetic combination of hormonally and cytotoxically effective formulations as in slow release Silastic capsules suitable for breast implantation such that said compositions are continuously released at relatively constant rates for longer periods and with minimum or no systemic toxicity than if said drug compositions were frequently administered orally at much higher doses to achieve the same results as by said low dose breast implants.

27. Anticancer products according to claim 18, wherein said anti-cancer products

comprising of single or synergetic combination of hormonally and cytotoxically

effective amounts of an anti-estrogen from the groups of tamoxifen, raloxifene, or

toremifene and a progesterone composition selected from the group consisting of

megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from

the corticosteroids group prednisolone in same or separate slow release injectable

microcapsules suitable for breast implantation.

28. Anticancer products according to claim 27, wherein said single or synergetic

combination of hormonally and cytotoxically effective amount of formulations as

injectable microcapsules suitable for breast implantation such that said compositions

are continuously released at relatively constant rates and the contents of said

compositions being kept in amounts effective to suppress tumor growth with

minimum or no systemic toxicity than if said drug compositions were frequently

administered orally at much higher doses to achieve the same results as by said low

dose breast implants.

29. Anticancer products according to claim 18, wherein said implant products

comprising of an anti-estrogen from the groups of tamoxifen, raloxifene, or

toremifene and a progesterone composition selected from the group consisting of

megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from

the corticosteroids group prednisolone and are made as separate or as mixtures of two or more thereof and fused with a lipoid carrier.

30. Anti-cancer prostatic implant products according to claim 18, wherein said

5 biodegradable breast implants comprising of an anti-estrogen from the groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected from the group consisting of megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from the corticosteroids group prednisolone and are made as separate or as mixtures of two or more thereof as injectable microcapsules.

31. Anti-cancer prostatic implant products of claim 18, wherein said breast implants

10 comprises of an anti-estrogen from the groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected from the group consisting of megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from
15 the corticosteroids group prednisolone and are made as separate or as mixtures of two or more thereof in Silastic capsules.

32. A slow-release hormonal breast implant method and products comprising single or synergetic combination of hormonally and cytotoxically effective compositions

20 selected from the an anti-estrogen groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected from the group consisting of megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from the corticosteroids

group prednisolone and they are fused with a lipoid carrier or encapsulated in Silastic capsules or formulated as injectable microcapsules as suitable slow-release breast implantation and implanting said products for the treatment of early and advanced stage breast cancers and as hormonal treatment combined with radiation.

5

33. A method and product of claim 32, wherein said hormone implant treatment of breast cancer is less-costly, less toxic and more convenient to the patient.

34. A method and product of claim 32, wherein said slow-release anti-estrogen implant treatment of the breast as hormonal prophylaxis against developing breast cancer by saturation of the breast tissue's binding sites for said anti-estrogens with high efficiency than by said anti-estrogen's daily oral administration at higher doses.

10

15

20